Thursday October 4, 2012 0 comments
BOULDER - Covidien (NYSE: COV) today announced U.S. Food and Drug Administration 510 (k) clearance and European Economic Area (EEA) CE Mark approval for its Nellcor Bedside Respiratory Patient Monitoring system.
The new system provides continuous monitoring of blood oxygenation and pulse rate, along with trend data to help clinicians detect and respond to dangerous respiratory events sooner.
The system is upgradeable onsite to accommodate new parameters and features, including Nellcor Respiration Rate software, reducing service disruptions and hospital costs.
"We are pleased to announce clearance to market the Nellcor Bedside Respiratory Patient Monitoring systems in the U.S. and the EEA," said Robert J. White, Covidien's president of respiratory and monitoring solutions.
"With this addition, we now offer an updated portfolio of industry-leading bedside monitoring solutions that meet unique care needs in both high- and low-acuity settings, thus enhancing patient safety in hospitals throughout the world."
The new system will be available in the U.S. and throughout the EEA in the next few months, the company said.
For more information, visit www.covidien.com.